title: Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL).
abstract: Thirty-five patients with a mean age of 60.6 years (44-78 years, 22 male, 13 female) with advanced low-grade non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), or prolymphocytic leukemia (PLL) were treated every 4 weeks with prednimustine 100 mg/m2 p.o. d 1-d 5 and mitoxantrone 8 mg/m2 i.v. d 1 and d 2. Seven patients had CLL, one lymphocytic NHL, two PLL, 13 immunocytoma, nine centroblastic/centrocytic NHL, and three centrocytic NHL. Twenty-five patients were pretreated. The subjective toxicity of the treatment was mild, with no WHO grade-3 alopecia, polyneuropathy, cardiotoxicity, mucositis, nausea, or vomiting. Hematologic side effects with WHO grade-4 granulopenia and thrombopenia were experienced by 26% and 23% of the patients, respectively. The overall response rate (CR+PR) was 72% for lymphoma patients and 37% for CLL patients, with a median remission duration of 14.6 months. The maximum response was achieved after a median of two treatment courses. Prednimustine with mitoxantrone is a subjectively well tolerated treatment for low-grade malignant NHL, to be further evaluated in phase-III studies. The regimen may shorten the duration of treatment, saving time-consuming out-patient visits and costs.
authors.affiliation: Department of Hematology and Oncology, Hannover Medical School, Federal Republic of Germany.
authors.forename: M
authors.initials: M
authors.lastname: Freund
authors.forename: S
authors.initials: S
authors.lastname: Wunsch-Zeddies
authors.forename: M
authors.initials: M
authors.lastname: Schäfers
authors.forename: J
authors.initials: J
authors.lastname: Wysk
authors.forename: I
authors.initials: I
authors.lastname: Seidel
authors.forename: W
authors.initials: W
authors.lastname: Hiddemann
authors.forename: A R
authors.initials: AR
authors.lastname: Hanauske
authors.forename: H
authors.initials: H
authors.lastname: Link
authors.forename: H J
authors.initials: HJ
authors.lastname: Schmoll
authors.forename: H
authors.initials: H
authors.lastname: Poliwoda
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000627:therapeutic use* / Q000633:toxicity; D011238:Prednimustine / Q000627:therapeutic use* / Q000633:toxicity
chemical_list: D011238:Prednimustine; D008942:Mitoxantrone